[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 239
1. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 01;13(15 Pt 1):4422-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions.
  • RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Serine Endopeptidases / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


2. Brunner AH, Sagmeister T, Kremer J, Riss P, Brustmann H: The accuracy of frozen section analysis in ultrasound- guided core needle biopsy of breast lesions. BMC Cancer; 2009;9:341
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the cases 42/59 (71.2%) were proved to be malignant and 17/59 (28.8%) to be benign in the definitive histology.
  • Immediate investigations of CNB is an accurate diagnostic tool and an important step in reducing psychological strain by minimizing the period of uncertainty in patients with breast tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Adv Nurs. 2000 Apr;31(4):752-8 [10759970.001]
  • [Cites] Breast Cancer Res Treat. 2007 Dec;106(3):399-406 [17318378.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):791-807 [10943278.001]
  • [Cites] J Ultrasound Med. 2001 Jan;20(1):43-9 [11149527.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):324-32 [11180078.001]
  • [Cites] Radiol Clin North Am. 2002 May;40(3):483-500, vi [12117188.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):193-5 [14747449.001]
  • [Cites] Cancer. 1974 Feb;33(2):310-7 [4812752.001]
  • [Cites] Cancer. 1980 Aug 15;46(4 Suppl):947-9 [7397673.001]
  • [Cites] Ann Surg. 1985 Dec;202(6):696-701 [4073982.001]
  • [Cites] Radiology. 1991 Aug;180(2):403-7 [1648757.001]
  • [Cites] Radiology. 1993 May;187(2):507-11 [8475299.001]
  • [Cites] Eur J Surg Oncol. 1994 Dec;20(6):711-4 [7995430.001]
  • [Cites] Radiology. 1998 Jul;208(1):251-60 [9646821.001]
  • [Cites] Radiology. 1998 Sep;208(3):717-23 [9722851.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jun;97(3):319-21 [16570117.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1191-9 [10789761.001]
  • (PMID = 19778424.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2759967
  •  go-up   go-down


3. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol; 2010 Jun;117(3):440-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
  • Our subject group consisted of women diagnosed with benign masses and early- and late-stage ovarian cancer.
  • RESULTS: More than half of the biomarkers tested were found to differ significantly between benign and malignant cases.
  • As individual markers, HE4 and CA-125 provided the greatest level of discrimination between benign and malignant cases, and the combination of these two biomarkers provided a higher level of discriminatory power than either marker considered alone.
  • Multivariate statistical analysis identified several multimarker panels that could discriminate early-stage, late-stage, and combined ovarian cancers from benign cases with similar or slightly improved SN/SP levels to the CA-125/HE4 combination; however, these larger panels could not outperform the 2-biomarker panel in an independent validation set.
  • CONCLUSIONS: Our findings serve to advance the development of blood-based screening methods for the discrimination of benign and malignant ovarian masses by confirming and expanding upon the superior utility of the CA-125/HE4 combination.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Cancer Suppl. 1988;3:61-7 [3209301.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):353-61 [3594371.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):203-9 [1468698.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):707-13 [7687515.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):402-5 [7535720.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):111-6 [7557595.001]
  • [Cites] Cancer. 1997 May 1;79(9):1647-55 [9128978.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1997 Mar-Apr;59(2):106-14 [9166881.001]
  • [Cites] Am Fam Physician. 1998 May 15;57(10):2471-6, 2479-80 [9614415.001]
  • [Cites] Oncology. 2004;67(3-4):225-30 [15557783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Hum Cell. 2004 Dec;17(4):203-9 [16035505.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):382-90 [16505113.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):448-58 [16885652.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):232-65 [18291115.001]
  • [Cites] Obstet Gynecol Clin North Am. 2008 Jun;35(2):271-84, ix [18486841.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1103-13 [18766180.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2647-56 [19351767.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2159-66 [20368574.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):141-5 [10843472.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] Obstet Gynecol. 2003 Sep;102(3):499-505 [12962932.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):662-6 [13678742.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Nurs Clin North Am. 1992 Dec;27(4):835-45 [1448359.001]
  • (PMID = 20334903.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642-03; United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / R01 CA098642-02; United States / NCI NIH HHS / CA / R01 CA098642-01A1; United States / NCI NIH HHS / CA / R01 CA108990-02; United States / NCI NIH HHS / CA / R01 CA108990-01; United States / NCI NIH HHS / CA / R01 CA108990-05; United States / NCI NIH HHS / CA / R01 CA108990-04; United States / NCI NIH HHS / CA / R01 CA108990-05S1; United States / NCI NIH HHS / CA / R01 CA098642-04; United States / NCI NIH HHS / CA / R01 CA108990-01A1; United States / NCI NIH HHS / CA / R01 CA108990-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS192224; NLM/ PMC2873171
  •  go-up   go-down


Advertisement
4. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA: Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol; 2008 Jan;108(1):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
  • We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers.
  • EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression.
  • We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18).
  • Over 74% of normal non-gynecologic tissues did not express MISIIR.
  • CONCLUSIONS: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies.
  • Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers.
  • [MeSH-major] Genital Neoplasms, Female / enzymology. Receptors, Peptide / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Animals. Blotting, Western. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transfection

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988723.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anti-Mullerian hormone receptor
  •  go-up   go-down


5. Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX: Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol Oncol; 2010 Feb;116(2):269-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
  • Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model.
  • Then, we tested VSV oncolytic therapy using the immune competent Wv mice that develop tubular adenomas, benign tumor lesions derived from ovarian surface epithelial cells.
  • The epithelial tumor lesions were greatly reduced in VSV-targeted ovarian tumors in the Wv mice.
  • The results demonstrated the explicit targeting of ovarian epithelial tumors by VSV in immune competent, ovarian tumor-bearing mouse models, and further support the utility of VSV as an effective and safe anti-cancer agent.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3605-11 [12839948.001]
  • [Cites] J Virol. 2003 Aug;77(16):8843-56 [12885903.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] J Cell Physiol. 1988 Mar;134(3):347-56 [2450877.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] EMBO J. 1990 Jun;9(6):1805-13 [1693331.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] J Virol. 2004 Dec;78(23):12747-61 [15542627.001]
  • [Cites] Viral Immunol. 2004;17(4):516-27 [15671748.001]
  • [Cites] Hepatology. 2005 Jan;41(1):196-203 [15619242.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):651-9 [17299401.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1325-36 [17392171.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Mol Med (Berl). 2008 Apr;86(4):363-77 [18214411.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4506-10 [18559493.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Mol Cell Biol. 2009 Sep;29(17):4766-77 [19581290.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):965-76 [16294217.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):349-58 [16186807.001]
  • [Cites] Curr Opin Mol Ther. 2006 Aug;8(4):322-30 [16955695.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57 [17077357.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • (PMID = 19932656.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083638-100010; United States / NCI NIH HHS / CA / R01 CA079716-11; United States / NCI NIH HHS / CA / CA095924-06; United States / NCI NIH HHS / CA / R01 CA099471-05; United States / NCI NIH HHS / CA / R01 CA095924-05; United States / NCI NIH HHS / CA / R01 CA79716; United States / NCI NIH HHS / CA / R01 CA099471; United States / NCI NIH HHS / CA / R01 CA75389; United States / NCI NIH HHS / CA / R01 CA079716; United States / NIAID NIH HHS / AI / R01 AI071193-01A2; United States / NIAID NIH HHS / AI / R01 AI071193; United States / NCI NIH HHS / CA / CA095924-05; United States / NCI NIH HHS / CA / CA083638-100010; United States / NCI NIH HHS / CA / CA128115-01A2; United States / NCI NIH HHS / CA / R01 CA095924-06; United States / NCI NIH HHS / CA / P01 CA128115-01A2; United States / NCI NIH HHS / CA / CA079716-11; United States / NIAID NIH HHS / AI / AI071193-01A2; United States / NCI NIH HHS / CA / P01 CA128115; United States / NCI NIH HHS / CA / P50 CA083638; United States / NIAID NIH HHS / AI / R01 AI079336; United States / NCI NIH HHS / CA / R01 CA095924; United States / NCI NIH HHS / CA / CA099471-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161338; NLM/ PMC2813895
  •  go-up   go-down


6. Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res; 2005 May 1;11(9):3320-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA.
  • Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied.
  • In contrast, no hK6 secretion was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and plasma concentrations (mean +/- SE) among normal healthy females (2.7 +/- 0.2 microg/L), patients with benign diseases (2.4 +/- 0.2 microg/L), and patients with endometrioid carcinoma (2.6 +/- 0.2 microg/L) were not significantly different.
  • In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005).
  • [MeSH-major] Biomarkers, Tumor / blood. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Kallikreins / blood. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867230.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


7. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • In recent years, immunohistochemistry with p16 antibodies has been used as a diagnostic aid in various scenarios in gynecologic pathology.
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


8. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


9. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R: The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol; 2006 Dec;103(3):802-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While the role of either soluble or matrix-immobilized protease in tumor invasion is well established, the part of cell surface PARs is beginning to emerge.
  • CONCLUSIONS: PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


10. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK: EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer; 2009 Jun 15;115(12):2684-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: EphA2, estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression levels were evaluated using immunohistochemistry in 139 endometrioid endometrial carcinoma (EEC) samples and in 10 benign endometrial samples.
  • RESULTS: High expression of EphA2 was detected in 48% of EEC samples versus 10% of benign samples.
  • EphA2 overexpression was associated significantly with high disease stage (P = .04), high tumor grade (P = .003), increased depth of myometrial invasion (P = .05), low ER expression (P = .01), low PR expression (P = .006), and high Ki-67 expression (P = .04).
  • Low ER and PR expression levels were associated with high tumor grade, positive lymph nodes, high Ki-67 expression, and high EphA2 expression.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] J Cell Biochem. 2002;85(4):714-20 [11968011.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3425-9 [12810680.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Gynecol Oncol. 1990 Jul;38(1):59-65 [2141316.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Oncogene. 1994 May;9(5):1461-7 [8152808.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):406-11 [7705676.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Prostate. 1999 Dec 1;41(4):275-80 [10544301.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1736-44 [10561210.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3250-5 [11309274.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Apr;10(2):271-88, viii [11382587.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • (PMID = 19396818.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA101642; United States / NCI NIH HHS / CA / CA101642-05; United States / NCI NIH HHS / CA / T32 CA101642-05; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA083639-10; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS241018; NLM/ PMC3139331
  •  go-up   go-down


11. Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, Knight B: Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol; 2005 Sep;98(3):409-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
  • OBJECTIVES: The obligate intracellular bacterium Chlamydia trachomatis is frequently found in association with benign proliferative, pre-neoplastic and malignant changes in cervical epithelium.
  • The cultures showed a 2-fold decrease in the expression of the gene coding for the tumor suppressor caveolin-1, and increased expression of the oncogene C-myc, a promoter of cervical carcinogenesis.
  • [MeSH-major] Caveolins / genetics. Cell Transformation, Neoplastic / genetics. Cervix Uteri / microbiology. Chlamydia trachomatis / physiology. Genes, Tumor Suppressor / physiology. Genes, myc / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / microbiology
  • [MeSH-minor] Caveolin 1. Chlamydia Infections / complications. Chlamydia Infections / genetics. Chlamydia Infections / microbiology. Female. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / microbiology. Humans. Interferon-gamma / pharmacology. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-myc / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation


12. Park KJ, Soslow RA, Sonoda Y, Barakat RR, Abu-Rustum NR: Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. Gynecol Oncol; 2008 Sep;110(3):316-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.
  • OBJECTIVE: To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions.
  • An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al. was also applied to the frozen and permanent section slides and compared to the final diagnosis.
  • RESULTS: There was 84% concordance between the frozen-section and final diagnosis using histology alone, vs. 95% concordance using the Ioffe scoring system.
  • One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin, which in retrospect, was a benign lesion and was correctly classified using the Ioffe system.
  • CONCLUSION: Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions, especially during frozen-section evaluation of the trachelectomy.
  • Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system, like that proposed by Ioffe et al., can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone.
  • [MeSH-minor] Adult. Female. Frozen Sections. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Retrospective Studies. Severity of Illness Index. Tumor Stem Cell Assay


13. Lee JM, Kim JW, Song JY, Lee JK, Lee NW, Kim SH, Lee KW: Adenocarcinoma arising in mature cystic teratoma: a case report. J Gynecol Oncol; 2008 Sep;19(3):199-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign cystic teratoma is recognized as one of the most common tumors in women during the reproductive age and frequently is treated by pelviscopic operation.
  • Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers.
  • We briefly reviewed literatures with regard to malignant transformation of a benign cystic teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):318-20 [17652549.001]
  • [Cites] Pathol Res Pract. 2006;202(7):531-5 [16713128.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):140-4 [16445624.001]
  • [Cites] Obstet Gynecol Surv. 1957 Dec;12(6):793-830 [13493921.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1326-33 [9788856.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2249-55 [9610706.001]
  • [Cites] Obstet Gynecol Surv. 2000 Dec;55(12):738-45 [11128910.001]
  • [Cites] Gynecol Oncol. 1992 Jun;45(3):248-53 [1319383.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):329-38 [3229546.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):597-9 [15297213.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):139-43 [14720146.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):338-41 [12893196.001]
  • [Cites] Arch Gynecol Obstet. 2002 Dec;267(2):107-9 [12439559.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):647-9 [8503739.001]
  • (PMID = 19471568.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676465
  • [Keywords] NOTNLM ; Adenocarcinoma / Malignant transformation / Mature cystic teratoma / Tumor marker
  •  go-up   go-down


14. Tjalma WA, Colpaert CG: Myxoid leiomyosarcoma of the vulva. Gynecol Oncol; 2005 Feb;96(2):548-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Myxoid leiomyosarcoma (MLMS) of the vulva is a mesenchymal tumor with only five reported cases in the literature.
  • Initial biopsies were benign.
  • However, clinically, this lesion was suspicious for a soft tissue tumor.
  • CONCLUSIONS: Vulvar myxoid leiomyosarcomas are rare and can be confused with other benign or malignant tumors.
  • It is important to be aware of this rare tumor variant, in order to plan appropriate treatment.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661250.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


15. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • MGB may be a promising new adjunctive marker in gynecologic pathology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


16. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


17. Hsu TL, Changchien CC, Huang CC, Lin H: Angioleiomyoma originating from the ovary of an eleven-year-old premenarchal girl. Gynecol Obstet Invest; 2008;65(4):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Angioleiomyoma (ALM) is a rare, benign neoplasm involving the peripheral soft tissues.
  • The final pathologic report of the resected tumor was consistent with an ALM.
  • [MeSH-minor] Adolescent. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • [CommentIn] Gynecol Obstet Invest. 2010;70(1):8-10 [20130412.001]
  • (PMID = 18196910.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA: Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol; 2010 Dec;116(6):1348-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the prevalence of appendiceal pathology in women undergoing surgery for a suspected ovarian neoplasm and the predictive value of intraoperative findings to determine the need for appendectomy at the time of surgery.
  • METHODS: Retrospective analysis of patients who underwent oophorectomy and appendectomy during the same surgical procedures at the University of Virginia Health System from 1992 to 2007.
  • Observations were stratified based on the nature (benign, borderline, or malignant) and histology (serous compared with mucinous) of the ovarian neoplasm, frozen compared with final pathological diagnosis, and the gross appearance of the appendix.
  • RESULTS: Among the 191 patients identified, frozen section was consistent with seven mucinous and 35 serous carcinomas, 16 serous and 33 mucinous borderline tumors, 71 mucinous and serous cystadenomas, and 29 cases of suspected metastatic tumor from a gastrointestinal primary.
  • Appendectomy is recommended when frozen section diagnosis is mucinous or serous ovarian carcinoma, borderline tumor or metastatic carcinoma of suspected gastrointestinal origin.
  • [MeSH-minor] Adult. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / secondary. Appendiceal Neoplasms / surgery. Appendix / pathology. Cecal Diseases / complications. Cecal Diseases / diagnosis. Cecal Diseases / surgery. Female. Frozen Sections. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099601.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, Wootipoom V, Thavaramara T, Buhachat R: Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand; 2010;89(2):182-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • POPULATION: Malignant ovarian germ cell tumor patients treated between January 1996 and December 2007.
  • Patients with malignant tumors arising from benign cystic teratoma were excluded.
  • Primary surgery was performed by a gynecologic oncologist in only 39.2% of cases.
  • Only preoperative tumor marker elevation was a significant poor prognostic factor for PFS.
  • Elevated preoperative serum tumor markers are a poor prognostic factor for PFS.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / blood. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961281.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


20. Bhosale P, Peungjesada S, Devine C, Balachandran A, Iyer R: Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):855-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging depicts the morphological details of the female pelvis and is useful for evaluating both benign and malignant cervical masses.
  • Clinical staging, as defined by FIGO (International Federation of Gynecologic Oncology), is based on the findings of physical examination, lesion biopsies, chest radiography, cystoscopy, and renal sonography and can be erroneous, depending on the stage of the disease, by 16% to 65%.
  • The prognosis of cervical cancer is determined not only by stage, but also by nodal status, tumor volume, and depth of invasion, none of which are included in the FIGO guidelines.
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Sensitivity and Specificity


21. Bratthauer GL, Saenger JS, Strauss BL: Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology; 2005 Dec;47(6):611-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included seven with benign secretory changes, 10 secretory carcinomas (nine invasive), one microglandular adenosis, three lobular neoplasias, four invasive ductal carcinomas, three clear cell carcinomas, one squamous cell carcinoma and one mucinous carcinoma.
  • [MeSH-major] Antibodies / metabolism. Breast / cytology. Breast / metabolism. Cell Differentiation. Genes, Tumor Suppressor. Phosphoproteins. Trans-Activators
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma / chemistry. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cytoplasm / metabolism. DNA-Binding Proteins. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Neoplasm Invasiveness. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324199.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


22. Cohen P, Tan AL, Penman A: The multidisciplinary tumor conference in gynecologic oncology--does it alter management? Int J Gynecol Cancer; 2009 Dec;19(9):1470-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary tumor conference in gynecologic oncology--does it alter management?
  • OBJECTIVE: To assess the role of the multidisciplinary tumor conference in patient management in a tertiary gynecologic oncology service.
  • METHODS: Data were analyzed from the records of all patients presented at the gynecologic oncology tumor conferences at Auckland City Hospital from August 1, 2005, to August 1, 2006.
  • Patient information including referral source, cancer site, stage, whether surgery had been performed before the tumor conference and if so where and by whom, and benign versus malignant was extracted from the records.
  • The radiological and pathological findings and diagnosis for each patient both before and after each tumor conference were compared.
  • A discrepancy was defined as a change in tumor site, histological type, grade, or stage that resulted from findings discussed at the conferences.
  • The most common changes to patient management that resulted from the tumor conferences were the addition of chemotherapy and surgery.
  • CONCLUSIONS: This study demonstrates that gynecologic oncology tumor conferences alter the diagnosis in a significant number of cases and therefore affect patient management.
  • [MeSH-minor] Female. Genital Neoplasms, Female / therapy. Humans. Multicenter Studies as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955920.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


23. Loizzi V, Cormio G, Resta L, Fattizzi N, Vicino M, Selvaggi L: Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecol Oncol; 2005 Apr;97(1):282-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Struma ovarii is a rare form of ovarian neoplasm composed entirely and predominantly of thyroid tissue.
  • CASE: We report an unusual presentation of a postmenopausal woman with benign struma ovarii associated with pseudo-Meigs syndrome, hypertiroidism, and elevated CA125 serum level, and a large complex right pelvic mass thereby mimicking an ovarian cancer.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoid Tumor / blood. Meigs Syndrome / blood. Ovarian Neoplasms / blood. Struma Ovarii / blood
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hyperthyroidism / blood

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790478.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


24. Young RH: Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear. Int J Gynecol Pathol; 2005 Jan;24(1):100-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear.
  • Selected outstanding books from the older literature on gynecologic pathology are reviewed with emphasis on drawing attention to the abundant helpful information and often outstanding illustrations that are worthy of review by present-day pathologists.
  • Each of them emphasizes the time-honored problem of mimicry of malignancy by diverse benign lesions or even aspects of normal histology.
  • Teilum's book contains a masterful account of the histopathology of germ cell tumors emphasizing a neoplasm with which his name will always be associated, the yolk sac tumor (endodermal sinus tumor).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626924.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol; 2008 May;109(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 100-fold CEACAM6 overexpression (qRT-PCR) was demonstrated in 13/16 (81%) borderline, low-grade, and high-grade invasive MON's, compared to 5/50 (10%) serous and 1/5 (20%) benign mucinous samples.
  • CEACAM6 expression was not different between borderline and invasive MON's (p=0.55) or across tumor stage (p=0.76).
  • None of the serous or benign mucinous tumors exhibited CEACAM6 staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / metabolism. Epithelium / metabolism. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Ovary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Staining and Labeling. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331757.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  •  go-up   go-down


26. Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW: B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res; 2006 Feb 1;66(3):1570-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B7-H4 was present at low levels in all sera but showed an elevated level in serum samples from ovarian cancer patients when compared with healthy controls or women with benign gynecologic diseases.
  • [MeSH-major] Antigens, CD80 / metabolism. Biomarkers, Tumor / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ascites / metabolism. Blotting, Western. CA-125 Antigen / blood. CA-125 Antigen / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Menopause / blood. Middle Aged. Sensitivity and Specificity. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452214.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


27. Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M: [Urine diacetylspermine as a novel tumor marker]. Rinsho Byori; 2005 Feb;53(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urine diacetylspermine as a novel tumor marker].
  • A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies.
  • Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia.
  • The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%.
  • These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / urine. Genital Neoplasms, Female / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796046.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  • [Number-of-references] 6
  •  go-up   go-down


28. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol; 2006 Dec;103(3):841-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
  • OBJECTIVES: To examine outcomes in women treated with conservative surgery for borderline ovarian tumor in a large population-based cohort with long-term follow-up.
  • METHODS: Women treated by conservative surgery for borderline tumor of the ovary from 1982-2004 within a large HMO setting were identified using electronic and tumor registry data.
  • The indications for and outcomes from any subsequent gynecologic surgery and the risk of recurrent ovarian borderline and malignant tumor were determined.
  • There were 21 recurrences with borderline tumor (11%) with a median time to first recurrence of 4.7 years; women treated by cystectomy recurred three times more often compared to women treated by oophorectomy (23% versus 7%).
  • During long-term follow-up, 19% of patients eventually underwent complete removal of ovarian tissue: in 8%, the surgery was prophylactic, in 5%, surgery was done for benign pathology, and in 6% for recurrent disease.
  • CONCLUSIONS: In this population-based HMO setting, 11% of women treated with conservative surgery for borderline tumor recurred; however, half of these recurrences were successfully managed by repeat conservative surgery, with only 6% of women overall needing eventual complete removal of ovaries for recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Cohort Studies. Disease-Free Survival. Female. Fertility. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / utilization. Health Maintenance Organizations. Humans. Medical Records. Middle Aged. Neoplasm Staging. Postoperative Complications. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793124.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down


30. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I: Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Protein Cell; 2010 Aug;1(8):711-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine tumors are the most common type of gynecologic neoplasm.
  • The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known.
  • Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established.
  • [MeSH-minor] Animals. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Down-Regulation. Female. Gene Deletion. Humans. Interferon Regulatory Factor-1 / biosynthesis. Interferon Regulatory Factor-1 / genetics. Leiomyoma / metabolism. Mice. Mice, Knockout

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21203912.001).
  • [ISSN] 1674-8018
  • [Journal-full-title] Protein & cell
  • [ISO-abbreviation] Protein Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factor-1; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC4875197
  •  go-up   go-down


31. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review. Arch Gynecol Obstet; 2010 Mar;281(3):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review.
  • BACKGROUND: Cystic tumors of ovary, whether benign, borderline, or malignant may be associated with mural nodule of various types, including sarcomas, sarcoma-like mural nodules (SLMN), and foci of anaplastic carcinoma.
  • Cases of serous borderline ovarian tumor with mural nodules of mixed type are very rare.
  • Left ureter was found to be dilated because of the infiltration of distal part by the tumor, so distal ureteral resection and neoureterocystostomy were performed.
  • Final pathology revealed borderline serous ovarian tumor with mural nodules which were consisted of SLMNs, multiple and sharply demarcated from the adjacent tumor, and sarcomatous nodules showing infiltrative appearance in metastatic regions.
  • [MeSH-minor] Anaplasia / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597831.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


32. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • OBJECTIVE: Wilms' tumor gene (WT1), located on chromosome 11, encodes a transcription factor that contributes to the carcinogenesis of uterine sarcomas.
  • Three slides from different sites of the tumor were analysed.
  • To compare, WT1 expression was also evaluated by IHC in benign endometrium (12) and benign endometrial polyps (5).
  • RESULTS: WT1 positivity was noticed in tumor cells and endothelial cells, lining the intratumoral blood vessels.
  • Comparing the staining patterns of the 3 different bioptic sites, tumor heterogeneity was demonstrated in the majority (72%) of samples.
  • [MeSH-major] Endometrial Neoplasms / genetics. Genes, Wilms Tumor
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


33. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P: Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparative proteomics identified the vitamin E-binding plasma protein afamin as a potential novel tumor marker for ovarian cancer.
  • The aim of this study was therefore to analyze afamin and apoA-IV in a large case-control study to evaluate the diagnostic utility of the two potential novel tumor markers in ovarian cancer patients.
  • We measured plasma concentrations of afamin and apoA-IV by means of a specific sandwich-type ELISA using affinity-purified polyclonal and monoclonal antibodies in 181 ovarian cancer patients of various clinical stages, 399 patients with benign gynecologic diseases, including endometriosis, and 177 controls and compared results with those for the conventional ovarian cancer tumor marker cancer antigen 125 (CA125).
  • Afamin concentrations decreased from a median of 70.7 mg/L (range, 34.6-116.1 mg/L) in healthy controls to 65.2 mg/L (range, 20.2-206.6 mg/L) in patients with benign gynecologic diseases to 56.0 mg/L (range, 4.7-96.0 mg/L) in ovarian cancer patients (P < 0.001 for all pairwise comparisons).
  • Similar results were obtained with apoA-IV concentrations decreasing from 13.0 mg/dL (range, 5.5-34.0 mg/dL) in controls to 11.7 mg/dL (range, 2.0-32.3 mg/dL) in benign conditions to 9.4 mg/dL (range, 0.3-29.5 mg/dL) in ovarian cancer (all P < 0.001).
  • Afamin, but not apoA-IV, added independent diagnostic information to CA125 and age for differentiating ovarian cancer from benign and healthy samples; the odds ratio of ovarian cancer was reduced by 44% for each doubling of afamin (P = 0.032).
  • [MeSH-major] Apolipoproteins A / blood. Biomarkers, Tumor / blood. Carrier Proteins / blood. Endometriosis / blood. Glycoproteins / blood. Neoplasms / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Case-Control Studies. Cross-Sectional Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. ROC Curve. Sensitivity and Specificity. Serum Albumin. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336561.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFM protein, human; 0 / Apolipoproteins A; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Serum Albumin; 0 / apolipoprotein A-IV
  •  go-up   go-down


34. Zhang PJ, Gao HG, Pasha TL, Litzky L, Livolsi VA: TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol; 2009 Jan;28(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, TTF-1 expression has been recently reported in carcinomas of other origins including female genital tract.
  • SPT24 and Refine/Bond Max autostainer was the most sensitive system among the primary antibodies and secondary detection/autostainers tested.
  • By using SPT24/Refine/Bond Max, TTF-1 reactivity could be detected in all major histologic subtypes of gynecologic tumors and up to 26% of all cases tested on routine surgical specimens and 6.4% on TMA.
  • TTF-1 was most frequently detected in uterine malignant mixed Müllerian tumor (82%), more common in uterine tumors than ovarian tumors, and more common in surgical specimen than TMA.
  • When present, tumor cells can be rarely positive or diffusely positive for TTF-1 reactivity.
  • In addition to malignant tumors, TTF-1 was also detected in benign tumors and benign tubal and endometrial epithelia.
  • TTF 1 immunostaining has the potential to misguide a pathologist to conclude an ovarian or endometrial tumor being a lung metastasis.
  • However, the role of TTF-1 in female genital tract and its tumors is unknown.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Antibodies, Monoclonal. Female. Humans. Sensitivity and Specificity. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047914.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


35. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR Jr: Predicting risk of malignancy in adnexal masses. Obstet Gynecol; 2010 Apr;115(4):687-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor morphology derived from ultrasonographic images, tumor size, tumor bilaterality, serum CA 125, and patient demographics were evaluated preoperatively in 395 patients undergoing surgery from 2001 to 2008.
  • Tumor morphology was classified as complex, solid, or cystic.
  • Preoperative findings were compared with tumor histologic findings at the time of surgery.
  • RESULTS: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors.
  • [MeSH-minor] Age Factors. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Humans. Middle Aged. Postmenopause. Premenopause. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2010 Apr;115(4):680-1 [20308824.001]
  • (PMID = 20308826.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


36. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, Takahashi S, Harada T, Sano A, Shomori K, Harada T, Kigawa J, Ito H, Terakawa N, Hasegawa J, Shiota G: A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep; 2007 Mar;17(3):541-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies.
  • By this method, we attempted to elucidate the diagnostic evaluation of serum hTERT mRNA for gynecologic malignancies.
  • In 174 female patients with gynecological lesions (47 with ovarian lesions, 63 with uterine lesions, 2 with malignancies in other gynecological lesions, and 62 benign lesions) and 20 healthy individuals, we measured serum hTERT mRNA and EGFR mRNA by using the newly developed real-time quantitative RT-PCR.
  • We examined their sensitivity and specificity in cancer diagnosis, clinical significance in comparison with conventional tumor markers, and their correlations with the clinical parameters by using multivariate analyses.
  • Serum hTERT mRNA showed higher values in patients with gynecologic cancers than in those with benign diseases and healthy individuals.
  • EGFR mRNA did not display any differences between the diseases. hTERT mRNA is useful for diagnosing gynecologic cancer and is superior to conventional tumor markers.
  • Therefore, serum hTERT mRNA is a novel and available biomarker for gynecologic malignancies.
  • [MeSH-major] Biomarkers, Tumor / blood. Genital Neoplasms, Female / blood. Genital Neoplasms, Female / diagnosis. Telomerase / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273731.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


37. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM, Gorelik E: Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol; 2006 Aug;102(2):244-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Circulating IL-8 and anti-IL-8 IgG concentrations were measured in blood sera from 44 patients with early stage (I-II) ovarian cancer, 50 patients with late stage (III-IV) ovarian cancer, 37 patients with benign pelvic masses, and 80 healthy women using the bead-based assay.
  • [MeSH-major] Autoantibodies / blood. Biomarkers, Tumor / immunology. Interleukin-18 / immunology. Interleukin-8 / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] CA-125 Antigen / blood. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434085.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Interleukin-18; 0 / Interleukin-8
  •  go-up   go-down


38. Barra Ade A, Gobbi H, de L Rezende CA, Gouvêa AP, de Lucena CE, Reis JH, Costa e Silva SZ: A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions. Diagn Cytopathol; 2008 Jan;36(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions.
  • The purpose of the study was to compare the accuracy of FNAC, CNB, and combined biopsy according to tumor size of suspicious breast lesions.
  • The lesions were divided in four groups according to the tumor size in the histopathology report: lesions smaller than 1 cm, between 1 and 2 cm, between 2 and 5 cm, and lesions greater than 5 cm.
  • The final surgical histopatology results identified 222 (84%) malignant cases and benign lesions summed 42 (16%).
  • [MeSH-minor] Breast / pathology. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064684.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Ben-Harosh S, Cohen I, Bornstein J: Bartholin's gland hyperplasia in a young woman. Gynecol Obstet Invest; 2008;65(1):18-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumors arising from the Bartholin's gland are very rare; the majority are benign.
  • As most instances of swelling in the Bartholin's gland area represent a duct cyst, clinicians tend to perform incision and drainage, rather than excision of the tumor.
  • [MeSH-minor] Adult. Female. Humans. Hyperplasia

  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel
  • (PMID = 17671387.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H: [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Zhonghua Fu Chan Ke Za Zhi; 2008 Dec;43(12):931-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: HE4 and CA(125) in the serum specimens of malignant ovarian tumor group (30 cases), benign ovarian diseases (110 cases; 45 benign ovarian tumor, 57 endometriotic diseases and 8 pelvic inflammation were included) and healthy women group (137 cases) were assayed double blindly.
  • (1) The median levels of HE4 and CA(125) were significantly higher in malignant ovarian tumor group (244 pmol/L and 601 kU/L respectively) than those of the benign ovarian diseases group (32 pmol/L and 22 kU/L respectively) and healthy women group (32 pmol/L and 11 kU/L respectively) (P = 0.000 - 0.029).
  • The median levels of CA(125) were also higher in endometriotic diseases and pelvic inflammation groups (53 and 41 kU/L respectively) than those of benign ovarian tumor group and healthy women group (12 and 11 kU/L respectively; P = 0.000 - 0.031). (2) The positive rate of HE4 was lower than that of CA(125) in malignant ovarian tumor group (P = 0.036).
  • HE4 was negative in benign diseases and healthy women groups.
  • But the positive rates of CA(125) were 56.1% and 5/8 respectively in endometriotic diseases and pelvic inflammation groups and there were significant differences compared with HE4 (P = 0.000). (3) The HE4 assay had advantage over the CA(125) assay in receiver operating characteristic-area under the curve (ROC-AUC) and sensitivity with a specificity of 100% when ovarian malignancy was compared with controls having benign diseases and healthy women, benign tumor or benign diseases groups respectively.
  • The CA(125) assay had advantage over the HE4 assay in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having healthy women group. (4) Combined assay of HE4 and CA(125) was better than CA(125) alone when ovarian malignancy was compared with controls having any group. (5) Combined assay was better than HE4 alone in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having benign diseases and healthy women or healthy women groups.
  • And combined assay was lower in the ROC-AUC and the sensitivity with specificity of 100% than HE4 when ovarian cancers were compared with controls having benign tumors or benign diseases groups respectively. (6) The diagnosis efficiency of the HE4 assay at the level 86 pmol/L determined in ROC curve with controls having benign diseases and healthy women group and at the 95% reference level 50 pmol/L of healthy women or 150 pmol/L recommended by the kit respectively was compared.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Epididymal Secretory Proteins / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Area Under Curve. Case-Control Studies. Double-Blind Method. Endometriosis / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Pelvic Neoplasms / blood. ROC Curve. Sensitivity and Specificity. Young Adult. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134334.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


41. Mittal K, Joutovsky A: Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol; 2007 Feb;104(2):362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.
  • All slides from the grossly recognized tumor were evaluated for the degree of atypia and mitotic counts within the leiomyosarcomas.
  • Morphologically benign tumor areas were identified in 5 of the 11 tumors.
  • These morphologically benign areas showed a p53 expression of 1% in each of the 4 cases, with low MIB-1 (5 to 15%) and high ER/PR expression (ER: 50-100%, PR: 10-100%).
  • The benign and malignant areas merged in all cases.
  • Morphologic and immunohistochemical spectrum of changes from benign to malignant is seen in 50% of LMS.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011615.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


42. Wang P, Wu X, Chen W, Liu J, Wang X: The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol; 2007 Mar;104(3):714-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The positive rates (100%; 86.4%; 88.2%) of LPA(1) mRNA in normal ovarian tissue, benign tumor and ovarian cancer were no significant difference (p>0.05).
  • The expression level of LPA(1) mRNA was significantly higher in normal ovarian tissue compared with that in benign tumor and in ovarian cancer tissue (p<0.01).
  • LPA(1) expression level was no significant difference in both benign tumor and ovarian cancer tissue (p>0.05).
  • LPA(2) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01); LPA(2) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(3) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01), LPA(3) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • The positive rates and expression level of LPA(2) and LPA(3) protein were significantly increased in ovarian cancer (92.6%; 92.6%) compared with that in benign tumor (45.5%; 45.5%) and that in normal ovarian tissue (43.8%; 43.8%) (p<0.01); LPA(2) and LPA(3) protein-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • [MeSH-minor] Adolescent. Adult. Aged. Blotting, Western. Female. Humans. Immunohistochemistry. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204312.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid
  •  go-up   go-down


43. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC: Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res; 2008 Feb 1;14(3):764-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
  • Therefore, the possibility of using autoantibodies directed against tumor-associated antigens as putative cancer markers is being more examined.
  • To do so, we developed an innovative technique called two-dimensional differential gel electrophoresis analysis of immunoprecipitated tumor antigens.
  • Further real-time reverse transcription-PCR and immunohistochemical studies confirmed that the S100A7 mRNA and protein were highly expressed in ovarian tumors but absent in normal and benign tissues.
  • Moreover, a preliminary study involving 138 patients confirmed that the plasma levels of anti-S100A7 antibodies are significantly elevated in early- and late-stage ovarian cancer patients compared with healthy controls and with patients with benign gynecologic diseases.
  • CONCLUSIONS: This shows that our approach is a valuable tool to successfully identify autoantibodies and tumor-associated antigens in cancer patients and that future research assessing their putative clinical usefulness would be worthwhile.
  • [MeSH-major] Antigens, Neoplasm / blood. Autoantibodies / blood. Ovarian Neoplasms / immunology
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunoglobulin G / blood. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245537.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA105009; United States / NCI NIH HHS / CA / R33CA103595; United States / NCI NIH HHS / CA / UO1CA86381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


44. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M: Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol; 2009 Jan;20(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Serum levels of YKL-40, cancer antigen 125 (CA 125), carbohydrate antigen 19-9 (CA19-9), and squamous cell carcinoma (SCC) antigen were determined by enzyme-linked immunosorbent assay in women with benign gynecologic disease (n=24), cervical malignancy (SCC, n=104; adenocarcinoma, n=37), and age-matched healthy controls (n=45).
  • Tumor-associated macrophages showed immunoreactivity for YKL-40 in 2 of 28 adenocarcinoma tissue samples, but adenocarcinoma cells themselves were nonimmunoreactive in all samples.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723551.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins
  •  go-up   go-down


45. Jeoung HY, Choi HS, Lim YS, Lee MY, Kim SA, Han SJ, Ahn TG, Choi SJ: The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors. J Gynecol Oncol; 2008 Dec;19(4):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.
  • OBJECTIVE: To evaluate the value of sonographic morphology indexing (MI) system and serum CA-125 levels in the assessment of the malignancy risk in patients with ovarian tumors.
  • CONCLUSION: The sonographic MI system is an accurate and simple method to differentiate a malignant tumor from a benign ovarian tumor.
  • The accuracy of the sonographic MI system improved when the serum CA-125 level was considered and ovarian teratomas were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 May;155(2):477-8 [3885313.001]
  • [Cites] Int J Gynecol Pathol. 1982;1(1):3-16 [7184889.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):46-50 [14529661.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):80-4 [11311766.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] CA Cancer J Clin. 1999 Sep-Oct;49(5):297-320 [11198956.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):454-9 [10831359.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):410-2 [10831351.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):3-7 [9570990.001]
  • [Cites] Obstet Gynecol. 1995 Jan;85(1):48-52 [7800323.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):174-8 [7959280.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):7-11 [8244178.001]
  • [Cites] Obstet Gynecol. 1991 Jul;78(1):70-6 [2047071.001]
  • [Cites] Gynecol Oncol. 1990 Oct;39(1):69-71 [2227575.001]
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • (PMID = 19471578.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676475
  • [Keywords] NOTNLM ; CA-125 antigen / ROC curve / Teratoma / Ultrasonogram (morphology indexing)
  •  go-up   go-down


46. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res; 2005 May 1;65(9):3726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial ovarian cancer derived from the human ovarian surface epithelium (HOSE) is the leading cause of death from gynecologic malignancies among American women.
  • Immunocytochemistry studies in 30 clinical specimens revealed overexpression of CYP1A1 in various types of ovarian cancers compared with benign epithelia and frequent localization of the enzyme to cancer cell nuclei.
  • [MeSH-minor] Alternative Splicing. Base Sequence. Benzo(a)pyrene / pharmacokinetics. Carcinogens / pharmacokinetics. Cell Line, Tumor. Cell Nucleus / enzymology. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Epithelium / enzymology. Epithelium / pathology. Estradiol / pharmacokinetics. Female. Humans. Isoenzymes. Mitochondria / enzymology. Molecular Sequence Data. Ovary / cytology. Ovary / drug effects. Ovary / enzymology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Subcellular Fractions / enzymology. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867368.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Isoenzymes; 0 / RNA, Messenger; 3417WMA06D / Benzo(a)pyrene; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


47. Rauvala M, Puistola U, Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol; 2005 Dec;99(3):656-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We measured, prior to primary surgery, the concentrations of these proteins in serum samples of 115 patients with an ovarian tumor: 63 with cancer, 6 with a low malignant potential tumor, and 46 with a benign tumor.
  • RESULTS: A high serum concentration of TIMP-1 at diagnosis was found to correlate with the malignant phenotype of an ovarian tumor.
  • An association was found between a high serum level of TIMP-1 and an advanced stage of the disease, a residual tumor>2 cm, poor response to cytotoxic treatment, shorter recurrence free time, and shorter cancer-related overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112717.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


48. Koyama T, Togashi K: Functional MR imaging of the female pelvis. J Magn Reson Imaging; 2007 Jun;25(6):1101-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional MR imaging of the female pelvis.
  • Recent developments in MR techniques have magnified the roles and potential of MRI in the female pelvis.
  • This article reviews the techniques and clinical applications of functional MRI (fMRI) of the female pelvis, including cine MRI, diffusion-weighted MRI (DWI), and dynamic contrast-enhanced (DCE)-MRI.
  • Cine MRI is a useful tool for evaluating uterine contractility, including sustained contraction and peristalsis, in a variety of conditions and gynecologic disorders, and for evaluating pelvic-floor weakness.
  • It also enables the quantitative evaluation of the apparent diffusion coefficient (ADC), which may be useful for distinguishing malignant from benign tissues and monitoring therapeutic outcome.
  • DCE-MRI has the potential to improve tumor detection and local staging, and can also provide quantitative information about perfusion of the tumor, which may be useful for both monitoring therapeutic effects and predicting therapeutic outcome.
  • Understanding the roles played by functional MR techniques in the female pelvic region is beneficial not only for determining clinical applications, but also for developing further investigations with MRI.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Magnetic Resonance Imaging / methods. Pelvis / pathology
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Uterine Contraction / physiology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17520731.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 101
  •  go-up   go-down


49. O'Meara AC, Giger OT, Kurrer M, Schaer G: Case report: Recurrence of a uterine tumor resembling ovarian sex-cord tumor. Gynecol Oncol; 2009 Jul;114(1):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Recurrence of a uterine tumor resembling ovarian sex-cord tumor.
  • BACKGROUND: Uterine tumors resembling ovarian sex-cord tumors are very rare uterine neoplasias that generally behave in a benign manner.
  • We report the case of a uterine tumor resembling an ovarian sex-cord tumor that recurred after hysterectomy.
  • Ultrasound examination showed a heterogeneous uterine tumor composed of cystic and solid parts.
  • Because of the patient's desire to preserve fertility, tumor resection was scheduled.
  • The final histological diagnosis was uterine tumor resembling ovarian sex-cord tumor.
  • CONCLUSION: Although uterine tumors resembling ovarian sex-cord tumors generally behave in a benign manner, they may in rare cases metastasize.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Metastasis / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Laparotomy. Recurrence

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406461.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


50. Ghander C, Lussato D, Conte Devolx B, Mundler O, Taïeb D: Incidental diagnosis of struma ovarii after thyroidectomy for thyroid cancer: functional imaging studies and follow-up. Gynecol Oncol; 2006 Aug;102(2):378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Struma ovarii is a rare ovarian germ-cell tumor containing thyroid tissue.
  • Histopathological analysis revealed a benign struma ovarii.
  • [MeSH-minor] Adult. Female. Humans. Thyroidectomy


51. Wang CJ, Chao A, Lai CH, Huang SY, Lee CL, Soong YK: Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses. J Laparoendosc Adv Surg Tech A; 2009 Oct;19(5):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses.
  • MATERIALS AND METHODS: Among the medical records of 324 patients with ovarian masses, 10 consecutive women of reproductive age with prior sexual activity and with large ovarian masses (10-27 cm) were evaluated.
  • The median (range) tumor size was 15.5 cm (range, 10-27), operative duration was 62 minutes (range, 31-110), the estimated blood loss 50 mL (range, 10-150), and the hospital stay was 2 days (range, 1-4).
  • [MeSH-major] Cystadenoma / surgery. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Laparoscopy. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715487.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC: Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2872-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the deadliest gynecologic cancer in the United States.
  • To address this, we evaluated the dysregulation of 204 molecules in a sample set consisting of serum from 294 patients, collected from multiple collection sites, under a well-defined Gynecologic Oncology Group protocol.
  • The population, weighted with early-stage cancers to assess biomarker value for early detection, contained all stages of ovarian cancer and common benign gynecologic conditions.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Area Under Curve. Autoimmune Diseases / blood. Female. Humans. Immunoassay / methods. Infection / blood. Middle Aged. ROC Curve. Specimen Handling. United States


53. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol; 2010 May;117(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter gene expression in benign and malignant ovarian tissue.
  • METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples.
  • RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue.
  • A significant difference between primary and recurrent tumor tissue was found in all four genes.
  • Changes in gene expression between benign samples and primary lesions were minor and not relevant.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenoma / genetics. Cystadenoma / metabolism. Cystadenoma / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. ROC Curve. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19922990.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0W860991D6 / Deoxycytidine; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


54. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R: Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol; 2005 Feb;96(2):368-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated Smad7 levels could then antagonize the TGF-beta pathway, leading to a reduction in tumor surveillance and potential cancer formation.
  • Our aim was to determine if Smad7 was in fact overexpressed in endometrial cancers and whether Smad7 RNA levels correlated with tumor grade or clinical endpoints.
  • Additionally, the endometrium from 18 patients who underwent hysterectomy for benign indications was collected as a control.
  • Given that many endometrial cancers have been shown to be TGF-beta-unresponsive, Smad7 should be investigated as a potential target to restore TGF-beta responsiveness and limit tumor growth.
  • [MeSH-minor] Cytoskeletal Proteins / biosynthesis. Female. Gene Expression. Humans. Middle Aged. Phosphorylation. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor, ErbB-2 / biosynthesis. Smad2 Protein. Smad3 Protein. Smad7 Protein. beta Catenin

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661223.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085257; United States / NCI NIH HHS / CA / CA 085257
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Neoplasm; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


55. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP: Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol; 2010 Nov;134(5):835-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with benign gynecologic diseases with high serum CA125 levels, nectin 4 was not detected in the majority of cases, suggesting that nectin 4 may serve as a potential biomarker that helps discriminate benign gynecologic diseases from ovarian cancer in a panel with CA125.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):143-8 [19135710.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6694-703 [19679554.001]
  • [Cites] Am J Clin Pathol. 2009 Dec;132(6):846-56 [19926575.001]
  • [Cites] Clin Chem. 2010 Feb;56(2):327-9 [20110452.001]
  • [Cites] Electrophoresis. 2010 Jan;31(4):599-610 [20162585.001]
  • [Cites] Gene. 2000 Sep 19;255(2):347-55 [11024295.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):43205-15 [11544254.001]
  • [Cites] Cancer Treat Res. 2002;107:61-97 [11775462.001]
  • [Cites] Mol Cell Probes. 2002 Apr;16(2):99-110 [12030760.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27006-13 [12011057.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 28;302(1):61-6 [12593848.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):1-10 [14968412.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):513-21 [15363801.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] FEBS Lett. 1998 Apr 24;426(3):386-91 [9600272.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):117-24 [10202133.001]
  • [Cites] Biol Chem. 2004 Oct;385(10):885-92 [15551862.001]
  • [Cites] Semin Cell Dev Biol. 2004 Dec;15(6):643-56 [15561584.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1032-42 [15564135.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19543-50 [15784625.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4319-28 [16618757.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5085-102 [16607281.001]
  • [Cites] BMC Cancer. 2007;7:73 [17474988.001]
  • [Cites] Curr Opin Cell Biol. 2007 Oct;19(5):593-602 [17942295.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):152-63 [17704261.001]
  • [Cites] J Biomol Screen. 2008 Jan;13(1):1-8 [18040052.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):161-74 [18317227.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20959669.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-05; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-05; United States / NCI NIH HHS / CA / R01-CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / LNIR protein, human
  • [Other-IDs] NLM/ NIHMS264396; NLM/ PMC3042138
  •  go-up   go-down


56. Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, Chang XH, Cui H: [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
  • OBJECTIVE: To investigate the value of human epididymis secretory protein 4(HE4) combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian malignant tumor.
  • METHODS: The level of HE4 and CA125 were measured by enzyme-linked immunosorbent assay (ELISA) in the serum specimens of 46 cases in endometriosis cyst group, 36 cases in malignant ovarian tumor group, 60 cases in benign ovarian diseases and 50 women in healthy women group.
  • (1) HE4: the median levels of HE4 were 52.4, 51.0, 50.0 pmol/L in group of endometriosis, normal control and benign ovarian tumor, which didn't show statistical difference.
  • However, HE4 was 507.5 pmol/L in ovarian cancer group, which was significantly higher than those of 3 groups (P<0.05). (2) CA125: there were significant different in median level of CA125 was observed as 743.0 kU/L in ovarian cancer, 84.9 kU/L in endoemtriosis, 15.4 kU/L in benign ovarian disease, and 11.5 kU/L in healthy women (P<0.05). (3) The single assay: when compared with that in endometriosis group, receiver operating characteristic area under the curve (ROC-AUC) were 0.933 in HE4 alone and 0.821 in CA125 alone assay in ovarian cancer group.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646446.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Epididymal Secretory Proteins
  •  go-up   go-down


57. Narayanan P, Iyngkaran T, Sohaib SA, Reznek RH, Rockall AG: Pearls and pitfalls of MR lymphography in gynecologic malignancy. Radiographics; 2009 Jul-Aug;29(4):1057-69; discussion 1069-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pearls and pitfalls of MR lymphography in gynecologic malignancy.
  • Dissemination of tumor to lymph nodes is one of the principal routes of metastatic disease.
  • The presence or absence of nodal disease is an important prognostic factor in gynecologic malignancies; thus, nodal staging is an integral part of the pretreatment assessment.
  • The contrast agent is taken up by macrophages within benign lymph nodes and allows differentiation from malignant nodes on the basis of alterations in signal intensity.
  • [MeSH-major] Dextrans. Diagnostic Errors / prevention & control. Ferrosoferric Oxide. Genital Neoplasms, Female / diagnosis. Image Enhancement / methods. Lymph Nodes / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis. Magnetite Nanoparticles

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605656.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / ferumoxtran-10; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  • [Number-of-references] 42
  •  go-up   go-down


58. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol; 2006 Jan;100(1):44-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to evaluate the expression of B7-H4 protein, recently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256178.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


59. Umekawa T, Tabata T, Tanida K, Yoshimura K, Sagawa N: Growing teratoma syndrome as an unusual cause of gliomatosis peritonei: a case report. Gynecol Oncol; 2005 Dec;99(3):761-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GTS is a synonym for "chemotherapeutic retroconversion", i.e., conversion from a metastatic immature teratoma to a mature tumor by chemotherapy.
  • Gliomatosis peritonei (GP) is a rare condition associated with ovarian teratomas of any grade, in which benign glial implants develop on the peritoneal surface.
  • CONCLUSIONS: Present case supported by review of the literatures suggests that GTS can be a part of GP, because both GTS and GP are associated with benign peritoneal glial implants regardless of grade of malignancy of their original tumor.
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125758.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Arora SK, Dey P, Saikia UN: Micronucleus in atypical urothelial cells. Diagn Cytopathol; 2010 Nov;38(11):811-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Student's t-test of MN scoring was highly significant (P < 0.000) in test (atypical urothelial cells) versus control group (benign urothelial cells).
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / urine. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / urine

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20049965.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Loffroy R, Nezzal N, Mejean N, Sagot P, Krausé D: Lipoleiomyoma of the uterus: imaging features. Gynecol Obstet Invest; 2008;66(2):73-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lipoleiomyoma is an extremely rare, benign, uterine tumor that requires no treatment when asymptomatic.
  • On T(2)-weighted MR images, fat content within the tumor was confirmed because of evident chemical shift artifact.To our knowledge, the findings provided by these three modalities used in combination have not been reported previously in the gynecologic literature.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Female. Histocytochemistry. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18431071.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB: A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol; 2009 Dec;22(12):1519-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyosarcomas are malignant smooth muscle tumors that occur most commonly in the gynecologic tract and soft tissue.
  • There are different diagnostic criteria of malignancy for smooth muscle tumors arising at gynecologic and soft tissue sites and they may be managed differently but determining the primary site of a smooth muscle tumor can be difficult in some cases.
  • In addition, the distinction between malignant and benign gynecologic tract smooth muscle tumors on morphologic grounds can be challenging.
  • Using a series of tissue microarrays that contain 245 cases of leiomyosarcomas (102 gynecologic) with survival data, and 49 cases of uterine leiomyoma, we examined the ability of selected immune-markers (estrogen receptor (ER) and WT1) to distinguish between leiomyosarcomas of gynecologic and nongynecologic origin.
  • In addition, we examined whether immunostains for p16, p53 and Ki-67 could distinguish between malignant and benign gynecologic smooth muscle tumors.
  • ER nuclear positivity was observed in 3 and 50% of the nongynecologic and gynecologic leiomyosarcomas, respectively (P<0.001).
  • Nuclear WT1 positivity was seen in 0 and 8% of the nongynecologic and gynecologic leiomyosarcomas, respectively (P<0.001).
  • 87% of primary gynecologic leiomyosarcomas and 2% of uterine leiomyomas showed diffuse (>or=50% of cells) p16 staining (P<0.001).
  • 23% of gynecologic leiomyosarcomas showed p53 immunopositivity (>or=50% of cells) whereas none of the leiomyomas were positive for p53 (P<0.001).
  • 65% of the gynecologic leiomyosarcomas and 0% of the leiomyomas exhibited >10% Ki-67 proliferation index (P<0.001).
  • Diffuse p16 and p53 immunopositivity and high Ki-67 proliferation index, singly or in combination, yielded an overall sensitivity of 92% and specificity of 98% for distinguishing between gynecologic leiomyosarcomas and leiomyomas and can be used as indicators of malignancy for gynecologic smooth muscle tumors.
  • Although ER positivity can be used to support the gynecologic origin of a leiomyosarcomas, nuclear WT1 immunostaining is of little use.
  • [MeSH-minor] Adult. Antibodies. Biomarkers, Tumor / analysis. Canada. Cell Nucleus / chemistry. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Diagnosis, Differential. Europe. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Predictive Value of Tests. Receptors, Estrogen / analysis. Sensitivity and Specificity. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. United States

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734847.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112270
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins
  •  go-up   go-down


63. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother; 2009 Jan;58(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Inflammatory cells can both suppress and stimulate tumor growth, and the influence of inflammatory cells on clinical outcome has been the focus of many studies.
  • METHODS: We studied 192 patients with epithelial ovarian cancer, 173 with benign ovarian tumors, 229 with benign gynecologic disease, and 405 healthy controls.
  • RESULTS: Preoperative NLR in ovarian cancer subjects (mean 6.02) was significantly higher than that in benign ovarian tumor subjects (mean 2.57), benign gynecologic disease subjects (mean 2.55), and healthy controls (mean 1.98) (P < 0.001).
  • [MeSH-major] Biomarkers, Tumor. Lymphocyte Count. Neoplasms, Glandular and Epithelial / pathology. Neutrophils / cytology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Retrospective Studies. Treatment Outcome


64. Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, Abdul-Karim FW, Gorodeski GI: Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol; 2007 Jul;106(1):233-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Tissue levels of P2X(7) protein and mRNA can differentiate effectively and accurately between normal and benign hyperplastic endometrial tissues from pre-cancerous and cancer tissues.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(8):1915-21 [10482924.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5568-79 [15319352.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):164-74 [15459114.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1342-56 [15728711.001]
  • [Cites] Obstet Gynecol. 2005 Aug;106(2):413-25 [16055605.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):388-92 [16051336.001]
  • [Cites] Public Health Nutr. 2005 Oct;8(7):912-9 [16277808.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):812-9 [16400639.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):804-11 [16400640.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77 [16364689.001]
  • [Cites] Hum Reprod. 2006 Apr;21(4):924-9 [16361289.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17228-37 [16624800.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):56-62 [16675538.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1906-13 [17035398.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1765-72 [11042572.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):11-23 [11255003.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):320-5 [11343902.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4590-6 [12464620.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1349-58 [15269006.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Differentiation. 1994 Apr;56(1-2):107-18 [7517899.001]
  • (PMID = 17482244.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015955-03; United States / NIA NIH HHS / AG / AG015955-06; United States / NIA NIH HHS / AG / AG015955-05; United States / NIA NIH HHS / AG / AG015955-09; United States / NIA NIH HHS / AG / R01 AG015955-06; United States / NIA NIH HHS / AG / AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-05; United States / NIA NIH HHS / AG / R01 AG015955-02; United States / NIA NIH HHS / AG / R01 AG015955-07; United States / NIA NIH HHS / AG / AG015955-07; United States / NIA NIH HHS / AG / AG015955-03; United States / NIA NIH HHS / AG / R01 AG015955-01A1; United States / NIA NIH HHS / AG / AG015955-02; United States / NIA NIH HHS / AG / AG15955; United States / NIA NIH HHS / AG / R01 AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-08; United States / NIA NIH HHS / AG / AG015955-08; United States / NIA NIH HHS / AG / AG015955-01A1; United States / NIA NIH HHS / AG / R01 AG015955; United States / NIA NIH HHS / AG / R01 AG015955-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7
  • [Other-IDs] NLM/ NIHMS47290; NLM/ PMC2398694
  •  go-up   go-down


65. Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, Kamiura S, Kimura T: Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecol Obstet Invest; 2008;66(1):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Uterine leiomyomas are the most common gynecological benign tumor and greatly affect reproductive health and well-being.
  • METHODS: The case patients were 213 women who underwent hysterectomy or myomectomy for fibroids, and the control subjects were 159 women who underwent operation for benign indications other than fibroids.
  • [MeSH-minor] Adult. Blood Glucose. Blood Preservation. Body Mass Index. Female. Humans. Hysterectomy. Middle Aged. Mortality. Risk Factors. Triglycerides

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18230910.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Triglycerides
  •  go-up   go-down


66. Piura B: Placental site trophoblastic tumor--a challenging rare entity. Eur J Gynaecol Oncol; 2006;27(6):545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor--a challenging rare entity.
  • Placental site trophoblastic tumor (PSTT) is a challenging rare variant of gestational trophoblastic disease (GTD) with variable characteristics.
  • Historically, it was first described in 1895 and was considered a benign lesion until Scully and Young recognized its malignant potential in 1981.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Trophoblastic Tumor, Placental Site / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers. Female. Humans. Pregnancy. Prognosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290581.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Number-of-references] 23
  •  go-up   go-down


67. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol; 2005 Jul;98(1):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate and compare autocrine expression and production of interleukin-6 (IL-6), a pleiotropic cytokine involved in the resistance to cytotoxic agents and inhibition of anti-tumor immune function in endometrial carcinoma in vitro as well as in vivo.
  • Secretion of IL-6 protein by 6 primary endometrial tumor cultures including USPC and EC was measured using a sensitive enzyme-linked immunosorbent assay (ELISA) in vitro.
  • Finally, IL-6 concentration in 71 serum samples including 20 apparently healthy women, 19 women with benign abdominal diseases, 19 women with primary EC, and 13 USPC patients was studied.
  • IL-6 serum concentrations between normal healthy females (range 0.01-21.23 pg/ml; mean 3.1 pg/ml) and benign disease patients (range 0.01-95.77 pg/ml; mean 13.07 pg/ml) were not statistically different.
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15904949.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6
  •  go-up   go-down


68. Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR: Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol; 2010 Apr;202(4):371.e1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Up-regulation of glycolysis has been demonstrated in multiple tumor types and is believed to originate as an adaptive response to the selective pressure of the tumor microenvironment.
  • RESULTS: Ovarian carcinoma cells overexpress Glut1, pAkt, and pmTOR compared with benign ovarian epithelial cells.
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antimetabolites / pharmacology. Cell Line, Tumor. Deoxyglucose / pharmacology. Female. Glucose Transporter Type 1 / metabolism. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20138251.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Glucose Transporter Type 1; 0 / Intracellular Signaling Peptides and Proteins; 0 / SLC2A1 protein, human; 9G2MP84A8W / Deoxyglucose; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


69. Kim TJ, Rho SB, Choi YL, Choi CH, Lee JW, Bae DS, Ahn G, Lee JH, Kim BG: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol; 2006 Jul;37(7):906-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate TIMP-2 level in serous ovarian tumor tissues and to understand further the role of TIMP-2 protein in ovarian tumorigenesis.
  • The expression of TIMP-2 was assessed by immunohistochemistry in a total of 57 ovarian specimens, including 5 normal ovaries, 12 benign serous cystadenomas, 20 serous borderline tumors, and 20 serous carcinomas.
  • In addition, we transfected a TIMP-2 plasmid into the gynecologic cancer cell lines SKOV-3, 2774, and HeLa and then assayed cell growth, apoptosis, and MMP-2 activation.
  • We found that TIMP-2 immunostaining was significantly more frequent in serous carcinomas, mainly in tumor epithelium, compared with cells of the other tissues studied.
  • These findings suggest that TIMP-2 may function to favor tumor growth in serous ovarian tumorigenesis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Blotting, Western. Cisplatin / pharmacology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. HeLa Cells. Humans. Immunohistochemistry. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784992.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol; 2007 Dec;107(3):526-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
  • OBJECTIVE: Currently available tumor markers for ovarian cancer are still inadequate in both sensitivity and specificity to be used for population-based screening.
  • The four tumor marker values were then used as inputs to an ANN derived using a training set from 100 apparently healthy women, 45 women with benign conditions arising from the ovary and 55 invasive epithelial ovarian cancer patients (including 27 stage I/II cases).
  • A separate validation set from 27 apparently healthy women, 56 women with benign conditions and 35 women with various types of malignant pelvic masses was used to monitor the ANN's performance during training.
  • An independent test data set from 98 apparently healthy women and 52 early stage epithelial ovarian cancer patients (38 stage I and 4 stage II invasive cases and 10 stage I borderline ovarian tumor cases) was used to evaluate the ANN.
  • CONCLUSIONS: The combined use of multiple tumor markers through an ANN improves the overall accuracy to discern healthy women from patients with early stage ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):56-61 [10094881.001]
  • [Cites] Lancet. 1997 Aug 16;350(9076):469-72 [9274582.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):216-20 [10228904.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):582-8 [10931457.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Cancer Treat Res. 2002;107:61-97 [11775462.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:204-12 [12095945.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gynecol Oncol. 1985 Sep;22(1):115-20 [2410329.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):414-6 [2418395.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):7-14 [2452773.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62 [1957862.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1025-9 [8490496.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):111-6 [7557595.001]
  • [Cites] Lancet. 1996 Jan 6;347(8993):12-5 [8531540.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2004-10 [8634992.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • (PMID = 17920110.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA83639; United States / NCI NIH HHS / CA / CA083639-07; United States / NCI NIH HHS / CA / U24 CA115102; United States / NCI NIH HHS / CA / CA115102-03; United States / NCI NIH HHS / CA / P50 CA083639-07; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / U24 CA115102-03; United States / NCI NIH HHS / CA / CA080459-01; United States / NCI NIH HHS / CA / R43 CA080459-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / Mucin-1; 81627-83-0 / Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS35835; NLM/ PMC2171045
  •  go-up   go-down


71. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC: Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol; 2009 Sep;114(3):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, median calprotectin concentration was elevated in the endometrial cancer group as compared to women with invasive ovarian cancer, borderline ovarian tumor and benign ovarian tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577278.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


72. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


73. De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, Bonomo L: Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging; 2009 Nov;34(6):696-711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls.
  • The utilization of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in combination with computed tomography (CT) in the assessment of gynecologic malignancies has been rapidly growing in recent years; however, its role in clinical practice has yet to be established.
  • Increased uptake has also been reported in many benign pelvic processes and in premenopausal patients; endometrial activity changes cyclically, whereas increased ovarian uptake may be functional.
  • FDG PET-CT has an emerging role in staging nodal disease and in the evaluation of local recurrence or peritoneal spread of gynecologic malignancies and is also useful in monitoring response to therapy and in long-term follow-up.
  • FDG PET-CT is most suitable in patients with high tumor markers and negative or uncertain conventional imaging data.
  • [MeSH-major] Fluorodeoxyglucose F18. Genital Neoplasms, Female / radiography. Genital Neoplasms, Female / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Sensitivity and Specificity. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791682.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 75
  •  go-up   go-down


74. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down


75. Yang JH, Shi YF, Cheng Q, Deng L: Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecol Oncol; 2006 Feb;100(2):294-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: AQP5 is mainly localized in the basolateral membranes of benign tumor cells, the apical and basolateral membrane of borderline cells and scattered in the membrane of malignant cells and almost no or weak staining in normal ovarian epithelium.
  • The AQP5 expression in ovarian malignant and borderline tumors was significantly higher than that of benign tumors (P < 0.05) and normal tissue (P < 0.05).
  • [MeSH-minor] Adolescent. Adult. Aged. Ascites / metabolism. Ascites / pathology. Blotting, Western. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242760.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP5 protein, human; 0 / Aquaporin 5; 0 / RNA, Messenger
  •  go-up   go-down


76. Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS: Clinical characteristics of struma ovarii. J Gynecol Oncol; 2008 Jun;19(2):135-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Struma ovarii is a rare tumor.
  • The treatment of benign struma ovarii is surgical resection only.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):698-707 [16681750.001]
  • [Cites] Ceylon Med J. 2004 Sep;49(3):90-1 [15524228.001]
  • [Cites] Am J Obstet Gynecol. 1961 Apr;81:752-62 [13766579.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] J Nucl Med. 1988 Feb;29(2):263-5 [2831319.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):178-82 [3297279.001]
  • [Cites] Br J Radiol. 1990 May;63(749):360-3 [2379061.001]
  • [Cites] J Reprod Med. 1983 Jun;28(6):415-9 [6887150.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):337-43 [6821820.001]
  • [Cites] Ann Intern Med. 1970 Jun;72(6):883-93 [5448747.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):543-8 [12798728.001]
  • [Cites] J Ultrasound Med. 2000 Dec;19(12):857-61 [11127011.001]
  • [Cites] Postgrad Med J. 1999 Oct;75(888):617-8 [10621907.001]
  • (PMID = 19471561.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676458
  • [Keywords] NOTNLM ; Dermoid tumor / Malignancy / Struma ovarii
  •  go-up   go-down


77. Canis M, Farina M, Jardon K, Rabischong B, Rivoire C, Nohuz E, Botchorishvili R, Pouly JL, Mage G: [Laparoscopy and gynecologic cancer in 2005]. J Gynecol Obstet Biol Reprod (Paris); 2006 Apr;35(2):117-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopy and gynecologic cancer in 2005].
  • All the surgical procedures, which may be required to treat a gynecologic cancer, can be performed endoscopically.
  • Animal studies suggested that the risk of tumor dissemination in non traumatized peritoneum is higher after a pneumoperitoneum than after a laparotomy.
  • Changing these parameters we may, in the future, be able to create a peritoneal environment adapted to oncologic patients in order to prevent or to decrease the risks of peritoneal dissemination and/or of postoperative tumor growth.
  • In contrast restaging of an early ovarian cancer initially managed as a benign mass, is a good indication of the laparoscopic approach.
  • Teaching and diffusion of endoscopic oncological techniques are among the major challenges of gynecologic surgery within the next few years.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Laparoscopy
  • [MeSH-minor] Animals. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / epidemiology. Peritoneal Neoplasms / etiology. Pneumoperitoneum, Artificial / adverse effects. Risk Factors. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575358.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 190
  •  go-up   go-down


78. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B: Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol; 2010 Sep;118(3):237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: GDF-15 concentration was measured by immunoradiometric assay in plasma samples from patients with invasive ovarian cancer (n=125), borderline ovarian tumor (BOT, n=43), and benign ovarian tumor (n=144), from healthy women (n=40), as well as in effusion samples (n=44) from women with advanced ovarian cancer.
  • RESULTS: Median plasma GDF-15 concentration was elevated in ovarian cancer as compared to healthy controls and women with benign ovarian tumors or BOT (p<0.001).
  • GDF-15 protein was cytoplasmatically expressed in serous tumor cells and detectable in high concentrations in effusion samples.
  • [MeSH-major] Biomarkers, Tumor / blood. Growth Differentiation Factor 15 / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Immunohistochemistry. Immunoradiometric Assay. Middle Aged. Ovarian Diseases / blood. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20576287.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15
  •  go-up   go-down


79. Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL Jr, Deavers M, Marincola FM, Yang P, Newman RA: Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res; 2007 Oct 1;13(19):5736-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
  • EXPERIMENTAL DESIGN: We first employed electrospray tandem mass spectrometry to determine tissue-specific concentrations of the eicosanoids prostaglandin E2 (PGE2), the hydroxyeicosatetraenoic acids (12-HETE and 5-HETE), and leukotriene (LTB4), selected for tumor growth potential, and two other bioactive lipids (15-HETE and 13-HODE) with tumor cell proliferation interference potential.
  • Tissues used included EOC tumor, tumor-free malignant peritoneum (MP), and benign peritoneum (BP) from patients with benign pelvic disease.
  • RESULTS: (a) Eicosanoid products were detected in tumor, MP, and BP specimens.
  • Neither 15-HETE nor 13-HODE showed a significant opposite trend toward levels found in BP. (b) Tissue specimens representing common EOC histotypes showed strong coexpressions of cyclooxygenases (COX-1) and prostaglandin E synthases (PGES-1) on tumor cells, whereas intratumoral or peritumoral MO/MA coexpressed COX-1 and COX-2 and PGES-1 and PGES-2, respectively. (c) cDNA microarray analysis of MP, BP, and tumor showed that a number of eicosanoid and arachidonic acid pathway genes were differentially expressed in MP and BP compared with tumor, except for CYP2J2, which was increased in tumors.
  • CONCLUSIONS: Elevated levels of eicosanoid metabolites in tumors and differential expression of eicosanoid and arachidonic acid pathway genes in the peritoneum support the involvement of bioactive lipids in the inflammatory tumor environment of EOC.
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Arachidonic Acid / chemistry. Dinoprostone / metabolism. Female. Gene Expression Profiling. Humans. Inflammation. Lipids / chemistry. Microscopy, Confocal. Models, Biological. Receptors, Cell Surface / biosynthesis. Spectrometry, Mass, Electrospray Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908963.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / Eicosanoids; 0 / Lipids; 0 / Receptors, Cell Surface; 27YG812J1I / Arachidonic Acid; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


80. Redman R, Wilkinson EJ, Massoll NA: Uterine-like mass with features of an extrauterine adenomyoma presenting 22 years after total abdominal hysterectomy-bilateral salpingo-oophorectomy: a case report and review of the literature. Arch Pathol Lab Med; 2005 Aug;129(8):1041-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyoma is a benign tumor composed of smooth muscle and benign endometrium.
  • An understanding of the müllerian system suggests that either an embryologic malformation or a differential multipotentiality existing in the subcoelomic tissues in response to hormonal stimulation results in a supernumerary müllerian structure like a uterus, as observed in this case.
  • It is most likely that this uterine-like mass arose from the tissues of the secondary müllerian system in response to estrogenic stimulation.
  • [MeSH-major] Adenomyoma / pathology. Gynecologic Surgical Procedures. Neoplasms, Hormone-Dependent / diagnosis. Uterine Neoplasms / pathology. Uterus / pathology
  • [MeSH-minor] Estrogen Replacement Therapy / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Middle Aged. Mullerian Ducts / drug effects. Mullerian Ducts / pathology. Ovariectomy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048397.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the most lethal gynecologic malignancy.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.


82. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol; 2006 Mar;100(3):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: AP-2gamma was detected in the nucleus of tumor cells in 28/75 (37%) borderline tumors, 13/22 (59%) FIGO stage I carcinomas, and 255/306 (83%) advanced-stage carcinomas (P < 0.001, Chi-square test).
  • Benign ovaries were uniformly negative.
  • CONCLUSIONS: AP-2gamma expression is upregulated in advanced-stage ovarian carcinoma compared to early-stage carcinomas, borderline tumors, and the ovarian surface epithelium, and AP-2gamma is specifically localized to cancer cells in effusions, suggesting a role in tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-kit / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216317.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


83. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


84. Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, Lewin S, Mutch MG, Dietz DW: Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum; 2005 Aug;48(8):1581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients also were incorporated from the gynecologic oncology service.
  • Accuracy of magnetic resonance vs. computed tomographic imaging for specific histologic tumor type was 28 vs. 18 percent, respectively.
  • All benign tumors were resected with normal histologic margins and none recurred (median follow-up, 22 months).
  • Whereas benign retrorectal tumors can be completely resected, curative resection of malignant retrorectal tumors remains difficult.
  • [MeSH-minor] Abdomen / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Blood Loss, Surgical. Blood Transfusion. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Perineum / surgery. Proctoscopy. Prospective Studies. Rectum / surgery. Retrospective Studies. Sex Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937630.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G: Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res; 2005 Dec 1;11(23):8364-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Lymphatic invasion and nodal metastasis plays a major role in the spread of cervical cancer; however, little is known about the mechanisms whereby tumor cells enter the lymphatic system.
  • EXPERIMENTAL DESIGN: We examined the intra- and peritumoral lymphatic vessel density (LVD) using D2-40 immunohistochemistry in 111 cervical squamous cell carcinomas and correlated them with vascular endothelial growth factor (VEGF)-C expression, clinicopathologic tumor features, and outcome.
  • RESULTS: Compared with benign cervix, intratumoral and peritumoral LVD was significantly increased (P < 0.0001).
  • High peritumoral, but not intratumoral, LVD showed significant correlation with high tumor stage, lymphatic invasion, and nodal metastasis.
  • CONCLUSIONS: Our findings suggest a potential role for VEGF-C in tumor-induced lymphangiogenesis represented by high peritumoral LVD, which may be one of the mechanisms leading to lymphatic invasion and metastatic spread.
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphangiogenesis. Lymphatic Metastasis. Neoplasm Staging. Neoplasms / metabolism. Neoplasms / pathology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Prognosis. Survival Rate


86. Kanehara H, Bando Y, Tomita M, Kontani M, Takegoshi Y, Tanaka N: Myxedema ascites with an extremely elevated CA125 Level: a case report. Endocr J; 2007 Aug;54(4):601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carbohydrate antigen 125 (CA125) is a tumor-marker frequently associated with ovarian malignancies; however, benign gynecologic conditions (e.g. ovarian cysts) commonly cause a smaller increase in CA125 levels.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Female. Humans. Thyroxine / therapeutic use

  • Genetic Alliance. consumer health - Myxedema.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641444.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


87. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol; 2010 Aug 1;118(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovarian cancers, normal ovaries, benign ovarian neoplasms, and fallopian tube fimbria.
  • RESULTS: EVI1 and EVI1s mRNAs were ubiquitously expressed in ovarian cancers and benign gynecologic tissues examined, with highest expression of both isoforms noted in the cancer samples.
  • EVI1 protein expression patterns were similar between serous ovarian cancer samples, fallopian tube fimbria, and benign neoplasms.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cisplatin / pharmacology. DNA Damage. Drug Delivery Systems. Female. Gene Knockdown Techniques. Humans. Middle Aged. Protein Isoforms. Proto-Oncogenes / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20462630.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


88. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao KR: Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In epithelial ovarian cancer, constitutively active Wnt signaling is restricted to one (endometrioid) tumor subtype.
  • RESULTS: All six epithelial ovarian cancer cell lines and 82% of the patient samples overexpressed nuclear hPygo2 compared with control cells and benign disease.
  • CONCLUSIONS: hPygo2 is unexpectedly widely expressed in, and required in the absence of, Wnt signaling for malignant growth of epithelial ovarian cancer, the deadliest gynecologic malignancy.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. In Vitro Techniques. Mice. Neoplasms, Experimental / therapy. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / PYGO2 protein, human
  •  go-up   go-down


89. Chang W, Oiseth SJ, Orentlicher R, Agarwal G, Yahr LJ, Cayten CG: Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl. Gynecol Oncol; 2006 May;101(2):342-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl.
  • BACKGROUND: Sclerosing stromal tumor of the ovary is a rare benign neoplasm that is usually unilateral in menstruating women with a mean age of 27.
  • CASE: An 11-year-old girl presented with asymptomatic bilateral sclerosing stromal tumor of the ovaries prior to menarche.
  • CONCLUSION: We herein report a unique case of bilateral sclerosing stromal tumor of the ovaries arising in a premenarchal girl.
  • [MeSH-minor] Child. Female. Humans. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403568.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Leiser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Soslow RA: Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol; 2006 Apr;101(1):86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A tissue microarray representing 36 uterine leiomyosarcomas and 19 uterine leiomyomas was created with 3 representative cores from each tumor.
  • In a multivariate analysis, tumor stage was the only independent significant prognostic factor (P = 0.002).
  • CONCLUSION: The significant differential expression of apoptotic and cell cycle regulatory proteins in uterine leiomyosarcoma as compared to benign smooth muscle tumors suggests that pathways involving these proteins may be important in the development of malignant disease and, therefore, could be potential targets for molecular therapies.
  • [MeSH-major] Apoptosis / physiology. Biomarkers, Tumor / biosynthesis. Cell Cycle / physiology. Cell Cycle Proteins / biosynthesis. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289259.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins
  •  go-up   go-down


91. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C: Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol; 2009 May;113(2):221-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
  • Another aim is to find new diagnostic markers, which may select patients at high risk for OC for quick referral to highly specialized centers in gynecologic oncology.
  • METHODS: The potential ability of the markers to discriminate between the four groups (208 benign ovarian tumor, 153 borderline ovarian tumor (BOT), 445 OC and 1333 age matched controls) in OC screening was examined.
  • We also constructed a risk assessment index (RAI) for discrimination between tumor groups based on these variables and menopausal status.
  • A very high probability of having OC or a benign tumor, respectively, was predicted by the RAI.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lectins, C-Type / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnosis. Ovarian Diseases / pathology. Postmenopause / blood. Premenopause / blood. Preoperative Care. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261323.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Lectins, C-Type; 109489-77-2 / tetranectin
  •  go-up   go-down


92. Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Chalumeau N, Francès C, Cacoub P, Papo T, Cormont S, Touitou Y, Grenier P, Valeyre D, Piette JC: Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev; 2005 May;14(5):1279-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
  • We have assessed the diagnostic values of serum tumor markers for the detection of solid cancer in dermatomyositis/polymyositis patients.
  • All the patients had complete physical examination, chest X-ray, echocardiogram, gastrointestinal tract endoscopic explorations, thoracoabdomino-pelvic computed tomography scan, and all women had gynecologic examination and mammogram.
  • Exclusion criteria for study were childhood dermatomyositis, inclusion body myositis, myositis associated with a connective tissue disease, prior history of cancer, and the presence of benign conditions known to elevate serum tumor markers.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Carcinoembryonic Antigen / blood. Dermatomyositis / diagnosis. Neoplasms, Unknown Primary / diagnosis. Polymyositis / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Cohort Studies. Female. France / epidemiology. Humans. Immunoradiometric Assay. Male. Middle Aged. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / epidemiology. Risk Factors

  • Genetic Alliance. consumer health - Myositis, inclusion body.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894686.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


93. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ: Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol; 2005 Jan;96(1):48-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
  • METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal.
  • Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types.
  • RESULTS: Tumor tissue engraftment rate was > 95%.
  • The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms.
  • Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
  • [MeSH-minor] Animals. Female. Humans. Immunophenotyping. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589579.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Ascites / etiology. Female. Gynecologic Surgical Procedures. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


95. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A: Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol; 2005 Dec;99(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, immunohistochemical (IHC) staining for EpoR in tissue specimens of normal, low malignant potential tumor, and epithelial ovarian carcinoma was performed.
  • IHC staining revealed limited EpoR expression in benign ovarian tissue and increased levels in ovarian low malignant potential (LMP) tumor and carcinoma.
  • This difference between benign ovarian tissue and carcinoma was found to be statistically significant using a quantitative scoring system.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cisplatin / pharmacology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Screening Assays, Antitumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051335.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Erythropoietin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML: Validation of referral guidelines for women with pelvic masses. Obstet Gynecol; 2005 Jan;105(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Guidelines for referring women with pelvic masses suspicious for ovarian cancers to gynecologic oncologists have been published jointly by Society of Gynecologic Oncologists (SGO) and the American College of Obstetricians and Gynecologists (ACOG).
  • Although the guidelines are evidence-based, their predictive value in distinguishing cancers from benign masses is unknown.
  • Fifty additional patients (4.8%) had cancers metastatic to the ovaries, and the remaining 667 (64.4%) had benign masses.
  • This distinction permits a rational approach for referring high-risk patients to a gynecologic oncologist for management.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. CA-125 Antigen / analysis. Female. Gynecology. Humans. Medical Oncology. Middle Aged. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Postmenopause. Practice Guidelines as Topic. Premenopause

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625139.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


97. Galani P, Kapetanakis S, Papadopoulos C, Dimitrakopoulou G, Kosma L, Lafoyianni S, Dimitrakova E, Papathanasiou J, Fiska A: Hypovolemic shock due to giant uterus leiomyoma detachment. Akush Ginekol (Sofiia); 2010;49(5):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyoma (UL) is the most common benign gynecologic tumor of the reproductive age females.
  • [MeSH-minor] Female. Humans. Middle Aged. Uterus / pathology. Uterus / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21265397.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


98. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J: Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett; 2010;31(3):375-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
  • OBJECTIVE: To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status.
  • We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.
  • POPULATION: 51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.
  • RESULTS: We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors.
  • Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors.
  • The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588232.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


99. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr: Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol; 2007 Sep;106(3):490-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Marker values have been compared to those in healthy controls and 115 patients with benign pelvic masses.
  • [MeSH-major] Biomarkers, Tumor / urine. Chorionic Gonadotropin, beta Subunit, Human / urine. Membrane Glycoproteins / urine. Ovarian Neoplasms / urine. Peptide Fragments / urine
  • [MeSH-minor] CA-125 Antigen / blood. Female. GPI-Linked Proteins. Glomerular Filtration Rate. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Biochemistry. 2003 May 6;42(17):4864-73 [12718527.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] BMC Cancer. 2004 May 12;4:19 [15140265.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Yale J Biol Med. 1989 Jul-Aug;62(4):367-78 [2596125.001]
  • [Cites] Fetal Diagn Ther. 1997 Nov-Dec;12(6):336-9 [9475362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):684-94 [15721412.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):432-41 [16428483.001]
  • (PMID = 17532030.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Peptide Fragments; 0 / mesothelin; 0 / urinary gonadotropin fragment
  • [Other-IDs] NLM/ NIHMS30261; NLM/ PMC3374586
  •  go-up   go-down


100. Zhao Y, Zong ZH, Xu HM: RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol; 2010 Mar;116(3):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue samples from normal ovaries, benign ovarian tumors, and epithelial ovarian cancer were collected.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Transfection. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022093.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / rho-Associated Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down






Advertisement